Search research articles
Contact Us
Filters
Showing results (71-80 of 86) with videos related to
Page
of 9
Sort By:
JAMA Oncology
|
July 15, 2021
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial
Scott N Gettinger, Mary W Redman, Lyudmila Bazhenova, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 6, 2024
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929
Nagla Abdel Karim, Jieling Miao, Karen L Reckamp, et al.
JCO Precision Oncology
|
September 7, 2023
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP)
Riha Vaidya, Joseph M Unger, Lu Qian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2025
Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: A Lung-MAP Study
Philip C Mack, Mary W Redman, Hanna Tukachinsky, et al.
Journal of the National Cancer Institute
|
January 10, 2023
Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I
Joseph M Unger, Lu Qian, Mary W Redman, et al.
Journal of the National Cancer Institute
|
January 19, 2018
Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424)
Ting-Yuan David Cheng, Amy K Darke, Mary W Redman, et al.
Cancers
|
June 13, 2025
Phase Ia/Ib Study of Afatinib with Capecitabine in Patients with Refractory Solid Tumors and Pancreaticobiliary Cancers
Gentry G King, Kelsey K Baker, Andrew L Coveler, et al.
The Lancet. Oncology
|
October 30, 2020
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol
Mary W Redman, Vassiliki A Papadimitrakopoulou, Katherine Minichiello, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2026
Erratum: Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators
Deborah B Doroshow, Ticiana A Leal, Saiama N Waqar, et al.
Cancer
|
May 3, 2017
T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas
Seth M Pollack, Qianchuan He, Jennifer H Yearley, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 86) with videos related to
Sort By:
Page
of 9
JAMA Oncology
|
July 15, 2021
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial
Scott N Gettinger, Mary W Redman, Lyudmila Bazhenova, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 6, 2024
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929
Nagla Abdel Karim, Jieling Miao, Karen L Reckamp, et al.
JCO Precision Oncology
|
September 7, 2023
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP)
Riha Vaidya, Joseph M Unger, Lu Qian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2025
Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: A Lung-MAP Study
Philip C Mack, Mary W Redman, Hanna Tukachinsky, et al.
Journal of the National Cancer Institute
|
January 10, 2023
Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I
Joseph M Unger, Lu Qian, Mary W Redman, et al.
Journal of the National Cancer Institute
|
January 19, 2018
Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424)
Ting-Yuan David Cheng, Amy K Darke, Mary W Redman, et al.
Cancers
|
June 13, 2025
Phase Ia/Ib Study of Afatinib with Capecitabine in Patients with Refractory Solid Tumors and Pancreaticobiliary Cancers
Gentry G King, Kelsey K Baker, Andrew L Coveler, et al.
The Lancet. Oncology
|
October 30, 2020
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol
Mary W Redman, Vassiliki A Papadimitrakopoulou, Katherine Minichiello, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2026
Erratum: Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators
Deborah B Doroshow, Ticiana A Leal, Saiama N Waqar, et al.
Cancer
|
May 3, 2017
T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas
Seth M Pollack, Qianchuan He, Jennifer H Yearley, et al.
Page
of 9